Possible role of IL-23 inhibitor in autoimmune hemolytic anemia

Naveen Premnath, Urvashi Pandey, Mohak Pandey, K. Venuprasad

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Rituximab and prednisone are commonly used treatments for autoimmune hemolytic anemia (AIHA), where the body's immune system attacks and destroys its red blood cells. However, some AIHA patients may become refractory to rituximab treatment, and this can result in continued hemolysis and persistent anemia, making it challenging for affected individuals to manage their symptoms. The underlying causes of rituximab refractoriness in AIHA patients can be complex and vary from patient to patient. Herein, we present a case of newly diagnosed warm and cold AIHA that remained in remission with an interleukin-23 inhibitor.

Original languageEnglish (US)
Pages (from-to)506-508
Number of pages3
JournalEuropean Journal of Haematology
Issue number3
StatePublished - Sep 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.


  • AIHA
  • autoimmune hemolysis
  • IL-17
  • IL-23
  • IL-23 Inhibitor
  • risankizumab

PubMed: MeSH publication types

  • Case Reports


Dive into the research topics of 'Possible role of IL-23 inhibitor in autoimmune hemolytic anemia'. Together they form a unique fingerprint.

Cite this